Get the Stockscreener App
11.68
3.36%
0.38
After Hours:
11.68
Stoke Therapeutics Inc stock is traded at $11.68, with a volume of 1.13M.
It is up +3.36% in the last 24 hours and up +3.27% over the past month.
Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. The company primarily operates in the U.S.
See More
Previous Close:
$11.30
Open:
$10.81
24h Volume:
1.13M
Relative Volume:
2.18
Market Cap:
$618.65M
Revenue:
$8.78M
Net Income/Loss:
$-104.70M
P/E Ratio:
-4.6166
EPS:
-2.53
Net Cash Flow:
$-82.68M
1W Performance:
-3.15%
1M Performance:
+3.27%
6M Performance:
-20.87%
1Y Performance:
+140.08%
1-Day Range:
$10.81
$11.84
1-Week Range:
$10.61
$12.58
52-Week Range:
$4.09
$17.58
Stoke Therapeutics Inc Stock (STOK) Company Profile
Name
Stoke Therapeutics Inc
Sector
Industry
Phone
781-430-8200
Address
45 WIGGINS AVENUE, BEDFORD, MA
Compare STOK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
STOK
Stoke Therapeutics Inc
|
11.68 | 618.65M | 8.78M | -104.70M | -82.68M | -2.37 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-14-24 | Resumed | Leerink Partners | Outperform |
| Mar-26-24 | Upgrade | TD Cowen | Market Perform → Outperform |
| Nov-20-23 | Resumed | JP Morgan | Neutral |
| Jul-25-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| May-01-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Apr-26-23 | Resumed | Canaccord Genuity | Buy |
| Jan-06-23 | Downgrade | BofA Securities | Buy → Underperform |
| Oct-24-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Jan-31-22 | Initiated | Jefferies | Buy |
| Dec-03-21 | Initiated | BofA Securities | Buy |
| Nov-22-21 | Upgrade | JP Morgan | Neutral → Overweight |
| May-18-21 | Initiated | UBS | Neutral |
| May-10-21 | Upgrade | Wedbush | Neutral → Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Feb-10-21 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-15-20 | Resumed | H.C. Wainwright | Buy |
| Dec-11-20 | Reiterated | Needham | Buy |
| Oct-23-20 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-29-20 | Resumed | JP Morgan | Neutral |
| Sep-29-20 | Initiated | Needham | Buy |
| Dec-18-19 | Initiated | Wedbush | Outperform |
| Nov-12-19 | Initiated | BTIG Research | Buy |
| Oct-25-19 | Initiated | H.C. Wainwright | Buy |
| Jul-15-19 | Initiated | Canaccord Genuity | Buy |
| Jul-15-19 | Initiated | Cowen | Outperform |
| Jul-15-19 | Initiated | Credit Suisse | Outperform |
| Jul-15-19 | Initiated | JP Morgan | Overweight |
View All
Stoke Therapeutics Inc Stock (STOK) Latest News
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Cuts Stock Position in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Chardan Capital Initiates Coverage of Stoke Therapeutics (STOK) with Buy Recommendation - MSN
Stoke Therapeutics (NASDAQ:STOK) Shares Gap DownHere's What Happened - MarketBeat
Chardan Capital Initiates Coverage on Stoke Therapeutics (NASDAQ:STOK) - MarketBeat
Jane Street Group LLC Acquires 255,028 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) - MarketBeat
(STOK) Proactive Strategies - Stock Traders Daily
Stoke Therapeutics (NASDAQ:STOK) Trading Down 5%What's Next? - MarketBeat
Companies Like Stoke Therapeutics (NASDAQ:STOK) Are In A Position To Invest In Growth - Yahoo Finance
Charles Schwab Investment Management Inc. Boosts Position in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Stoke Therapeutics (NASDAQ:STOK) pulls back 9.1% this week, but still delivers shareholders solid 136% return over 1 year - Simply Wall St
Fmr LLC Lowers Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK) - MarketBeat
Stoke Therapeutics’ (STOK) “Overweight” Rating Reiterated at Cantor Fitzgerald - Defense World
Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives $20.83 Average Target Price from Analysts - MarketBeat
Stoke therapeutics' general counsel sells $185,978 in stock - Investing.com
Stoke Therapeutics chief medical officer sells $33,595 in stock By Investing.com - Investing.com UK
Stoke therapeutics CEO Edward Kaye sells $78,837 in stock By Investing.com - Investing.com South Africa
Stoke Therapeutics, Inc. (NASDAQ:STOK) Shares Bought by BNP Paribas Financial Markets - MarketBeat
Stoke Therapeutics chief medical officer sells $33,595 in stock - Investing.com
Stoke Therapeutics chief medical officer Ticho sells $178,182 in stock By Investing.com - Investing.com Canada
Stoke therapeutics CEO Edward Kaye sells $78,837 in stock - Investing.com India
Stoke Therapeutics chief medical officer Ticho sells $178,182 in stock - Investing.com
Stoke therapeutics' general counsel sells $123,890 in stock - Investing.com
Stoke therapeutics' general counsel sells $123,890 in stock By Investing.com - Investing.com UK
(STOK) Investment Report - Stock Traders Daily
Stoke Therapeutics Gains FDA Breakthrough for Epilepsy Drug - MSN
Intech Investment Management LLC Invests $160,000 in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Stoke Therapeutics Presents New Open-Label Extension (OLE) Study - GuruFocus.com
Stoke Therapeutics Presents New Open-Label Extension (OLE) Study Data That Further Support the Potential for Zorevunersen as a Disease-Modifying Medicine for the Treatment of Dravet Syndrome - newsbreak.com
STOK Shares Up on FDA's Breakthrough Tag for Dravet Syndrome Drug - MSN
Stoke Therapeutics' Dravet Drug Shows Remarkable 87% Seizure Reduction in Clinical Data - StockTitan
Stoke Therapeutics, Inc. (NASDAQ:STOK) Stake Lifted by RTW Investments LP - MarketBeat
U.S. STOCKS Stoke Therapeutics, Foot Locker, Marvell - XM
Pure Storage Posts Upbeat Results, Joins Cross Country… - Inkl
Stoke Therapeutics' drug 'zorevunersen' earns FDA breakthrough tag; shares leap - Investing.com Nigeria
Stoke Therapeutics Shares Rise Premarket on Key FDA Designation - MarketWatch
Stoke Therapeutics Receives FDA Breakthrough Therapy Designation for Zorevunersen for the Treatment of Dravet Syndrome - Business Wire
Stoke Therapeutics' drug 'zorevunersen' earns FDA breakthrough tag; shares leap By Investing.com - Investing.com South Africa
Stoke Therapeutics CMO sells $120,698 in stock By Investing.com - Investing.com Canada
Stoke Therapeutics CMO sells $120,698 in stock - Investing.com India
Stoke Therapeutics Announces Plans to Present New Data that Support Zorevunersen as Potentially the First Disease-Modifying Medicine for Dravet Syndrome at the American Epilepsy Society 2024 Annual Meeting - Business Wire
Stoke Therapeutics: First Disease Modifying Therapy For Dravet, Still In Need Of Regulatory Clarity (NASDAQ:STOK) - Seeking Alpha
An RNA biotech draws the blueprint for a late-stage Dravet syndrome trial and beyond - PharmaVoice
Stoke Therapeutics (STOK) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - MSN
Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives $20.83 Average PT from Analysts - MarketBeat
Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Average Recommendation of “Buy” by Brokerages - Defense World
How To Trade (STOK) - Stock Traders Daily
Stoke Therapeutics (NASDAQ:STOK) Stock Price Down 8.3%What's Next? - MarketBeat
Redmile Group, LLC Adjusts Stake in Stoke Therapeutics Inc - GuruFocus.com
Los Angeles Capital Management LLC Grows Stock Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK) - MarketBeat
Stoke Therapeutics Inc Stock (STOK) Financials Data
Revenue
Net Income
Cash Flow
EPS
Stoke Therapeutics Inc Stock (STOK) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Allan Jonathan | GENERAL COUNSEL & CORP SEC |
Dec 09 '24 |
Sale |
13.61 |
13,666 |
185,978 |
21,476 |
| Kaye Edward M. MD | CEO |
Dec 09 '24 |
Sale |
12.99 |
6,786 |
88,158 |
61,885 |
| Ticho Barry | CHIEF MEDICAL OFFICER |
Dec 06 '24 |
Sale |
12.78 |
13,945 |
178,182 |
47,332 |
| Allan Jonathan | GENERAL COUNSEL & CORP SEC |
Dec 06 '24 |
Sale |
12.78 |
9,696 |
123,891 |
35,142 |
| Kaye Edward M. MD | CEO |
Dec 06 '24 |
Sale |
12.78 |
6,170 |
78,837 |
68,671 |
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):